Neuronetics Inc (STIM) Stock AnalysisSTIMStock AnalysisNeuronetics Inc

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Neuronetics Inc. (STIM) is a good buy right now due to its recent revenue growth of 9.1% year-over-year in Q2 2026, reaching $41.6 million, and a narrowed net loss of $3.4 million compared to $10.1 million in the prior year. The stock is currently priced at $2.94, significantly below the analyst price target of $5, indicating a potential upside of 70%. The main risk is its high debt to equity ratio of 284.28%, which could impact financial stability if not managed properly.

5 analysts cover STIM: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.00.